Valeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full Year
December 20, 2019 08:45 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting
December 09, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage
November 15, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced...
Valeritas Announces Third Quarter 2019 Financial Results
November 12, 2019 16:05 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,...
Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)
October 29, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019
October 24, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study
October 21, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their...
Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia
October 15, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting
October 10, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2019)
October 08, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...